AAM’s Leonard On Strategizing For Gene Therapies
Low Biosimilars Approval A Concern
As ‘hyper personalized’ medicines take hold, generic players need to examine the role they can play in democratizing access to gene therapies alongside complex generics and biosimilars, says AAM president and CEO Dan Leonard.
